Contribute Try STAT+ Today

File this under “What were they thinking?”

For the second time this year, Pfizer has made substantial price hikes on some of its medicines, a move that disregards blistering criticism of the pharmaceutical industry over the cost of prescription drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • geee,,,maybe its because all MEDICINE manufacturers are being sued by Adults who’s 30 year old ,”babies,”choose to use medicines like idiots,,,,,,maryw

  • If one wants to ‘observe’ that ‘Big Pharma’ is … uh, ‘s______g’ the customers, then using price increases on ‘the little blue pill’ is a fine point of emphasis.

  • New normal when one cannot create and develop new drugs for masses or expensive drugs for limited patients. Revenue has to go up to look good.

    • Shall we call this a ‘side effect’ of the Viagra patent extension to March 2020?

Comments are closed.